Filing Details

Accession Number:
0001209191-15-041823
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-05-12 17:31:29
Reporting Period:
2015-05-11
Filing Date:
2015-05-12
Accepted Time:
2015-05-12 17:31:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348649 Colucid Pharmaceuticals Inc. CLCD Pharmaceutical Preparations (2834) 203419541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1388325 A/S Novo Tuborg Havnevej 19
Hellerup G7 2900
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-05-11 1,756,563 $0.00 1,756,563 No 4 C Direct
Common Stock Acquisiton 2015-05-11 1,300,000 $10.00 3,056,563 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock SERIES C PREFERRED STOCK Disposition 2015-05-11 1,756,563 $0.00 1,756,563 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. Gives effect to the 1-for-40.7 reverse stock split of the capital stock of the Issuer, which became effective on April 17, 2015. The Series C Preferred Stock had no expiration date and automatically converted into the Issuer's common stock for no additional consideration on a one for one basis upon the closing of the Issuer's initial public offering.
  2. Represents a purchase from the underwriters in the Issuer's public offering.